SPECT Imaging with Tc-99m-Labeled HYNIC-FAPI-04 to Extend the Differential Time Window in Evaluating Tumor Fibrosis

The so-far used Ga-68- or F-18-labelled tracers are of a relative short time window in differentiating tumor fibrosis. SPECT applicable imaging probe, 99mTc-HYNIC-FAPI-04, was synthesized and evaluated in tumor cells and animal models of FAP-positive glioma and FAP-negative hepatoma, and then compared with 18F-FDG or 68Ga-FAPI-04 PET/CT. The radio-labeling rate of 99mTc-HYNIC-FAPI-04 was greater than 90%, and the radiochemical purity was >99% after purification with sep-pak C18 column. In vitro cell uptake experiments of 99mTc-HYNIC-FAPI-04 showed good FAP binding specificity, and the cellular uptake significantly decreased when blocked by DOTA-FAPI-04, reflecting the similar targeting mechanism of HYNIC-FAPI-04 and DOTA-FAPI-04. SPECT/CT imaging showed that U87MG tumor was distinguishable and of a high uptake of 99mTc-HYNIC-FAPI-04 (2.67 ± 0.35 %ID/mL at 1.5 h post injection (h P.I.), while tumor signal of FAP-negative HUH-7 was as low as 0.34 ± 0.06 %ID/mL. At 5 h P.I., U87MG tumor was still distinguishable (1.81 ± 0.20 %ID/mL). In comparison, although U87MG tumor was of obvious 68Ga-FAPI-04 uptake and clearly visible at 1 h P.I., the tumorous radioactive signals were fuzzy at 1.5 h P.I. 99mTc-HYNIC-FAPI-04 specifically bound to FAP-positive tumors and qualified with the ability of evaluating tumor fibrosis over longer time windows.

[1]  Ming-Rong Zhang,et al.  Highlight selection of radiochemistry and radiopharmacy developments by editorial board , 2022, EJNMMI Radiopharmacy and Chemistry.

[2]  Zeyu Zhang,et al.  Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Xuran Zhang,et al.  Preparation and Bioevaluation of 99mTc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein. , 2021, Molecular pharmaceutics.

[4]  B. Kilbas,et al.  Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy , 2021, EJNMMI Radiopharmacy and Chemistry.

[5]  S. Falco,et al.  The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities , 2021, Future science OA.

[6]  Nan Li,et al.  Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Tothill,et al.  FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology? , 2020, The Journal of Nuclear Medicine.

[8]  Haitao Zhao,et al.  Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  L. Terracciano,et al.  High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes , 2020, Frontiers in Oncology.

[10]  Hua Wu,et al.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Hua Wu,et al.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  J. Konvalinka,et al.  Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. , 2020, Biochimica et biophysica acta. Proteins and proteomics.

[13]  Shaoli Song,et al.  Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer , 2020, Scientific Reports.

[14]  T. Watabe,et al.  Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models , 2019, The Journal of Nuclear Medicine.

[15]  Fariborz Bagheri,et al.  Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer , 2020, Asia Oceania journal of nuclear medicine & biology.

[16]  J. Giglio,et al.  99mTc Labelling Strategies for the Development of Potential Nitroimidazolic Hypoxia Imaging Agents , 2019, Inorganics.

[17]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[18]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[19]  D. Jäger,et al.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts , 2018, The Journal of Nuclear Medicine.

[20]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[21]  D. McMillan,et al.  The Relationship Between Tumor Glucose Metabolism and Host Systemic Inflammatory Responses in Patients with Cancer: A Systematic Review , 2018, The Journal of Nuclear Medicine.

[22]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[23]  K. Pienta,et al.  Targeting the tumour stroma to improve cancer therapy , 2018, Nature Reviews Clinical Oncology.

[24]  S. Hosseinimehr,et al.  99mTc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging , 2018, Journal of Biomedical Science.

[25]  Jun Zhou 周 俊,et al.  Diagnosis performance of 99mTc-MIBI and multimodality imaging for hyperparathyroidism , 2017, Journal of Huazhong University of Science and Technology [Medical Sciences].

[26]  B. Bettencourt,et al.  Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis , 2016, Journal of Nuclear Cardiology.

[27]  O. Schilling,et al.  Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.

[28]  S. Bae,et al.  Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[29]  R. Palmqvist,et al.  High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis , 2013, Tumor Biology.

[30]  J. Capala,et al.  The role of nuclear medicine in modern therapy of cancer , 2012, Tumor Biology.

[31]  R. Najafi,et al.  Clinical evaluation of antimicrobial peptide [(99m)Tc/Tricine/HYNIC(0)]ubiquicidin 29-41 as a human-specific infection imaging agent. , 2009, Nuclear medicine and biology.

[32]  Harvey A. Ziessman,et al.  Comparison of SPECT/CT, SPECT, and Planar Imaging with Single- and Dual-Phase 99mTc-Sestamibi Parathyroid Scintigraphy , 2007, Journal of Nuclear Medicine.

[33]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[34]  M. Saurer,et al.  99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. , 2004, Bioconjugate chemistry.

[35]  Janet F Eary,et al.  Nuclear medicine in cancer diagnosis , 1999, The Lancet.

[36]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.